Skye Bioscience, Inc. Common Stock (SKYE NASDAQ) stock market data APIs
$1.5182
0(0%)
as of November 6, 2025
Try our APIs with
free plan!
Skye Bioscience, Inc. Common Stock Financial Data Overview
Price chart is built with
Anychart
Skye Bioscience, Inc., a clinical stage biopharmaceutical company, focuses on developing molecules that modulate G protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.
Prev. Close
1.5182
Open
1.5182
High
1.5856
Low
1.4929
52 wk Range
1.14-5.9
Market Cap
47 102 K
Shares Outstanding
30 988 K
EPS
-0.44
Beta
2.663
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Skye Bioscience, Inc. Common Stock (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Skye Bioscience, Inc. Common Stock data using free add-ons & libraries
Get Skye Bioscience, Inc. Common Stock Fundamental Data
Skye Bioscience, Inc. Common Stock Fundamental data includes:
- Net Revenue:
- EBITDA: -45 034 848
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-07
- EPS/Forecast: -0.22
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Skye Bioscience, Inc. Common Stock News
New
Skye Bioscience Late-Breaking Oral Abstract at ObesityWeek 2025 to Highlight Improvement in Rebound Weight Gain
SAN DIEGO, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and o...
Step Pharma announces the appointment of Dr Karen Smith as Chief Medical Officer
Karen Smith, MD, PhD, MBA, LLM, joins with over 25 years of global pharma and biotech experience, having contributed to more than 20 regulatory approvals Dr Smith's appointment will accelerate Step Ph...
Step Pharma announces the appointment of Dr Karen Smith as Chief Medical Officer
Step Pharma Karen Smith, MD, PhD, MBA, LLM, joins with over 25 years of global pharma and biotech experience, having contributed to more than 20 regulatory approvals Dr Smith's appointment will acce...
SKYE Stock Plunges 60% as Obesity Candidate Misses Key Phase II Goal
Shares of Skye Bioscience SKYE crashed 60% on Monday after the company failed to meet the key goal in a mid-stage proof-of-concept study of its only pipeline candidate, nimacimab, for obesity. The ph...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
